Latest Birchview Capital, LP Stock Portfolio

Birchview Capital, LP Performance:

2025 Q4: 10.83%YTD: 10.92%2024: 5.08%

Performance for 2025 Q4 is 10.83%, and YTD is 10.92%, and 2024 is 5.08%.

About Birchview Capital, LP and 13F Hedge Fund Stock Holdings

On 2026-02-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Birchview Capital, LP reported an equity portfolio of $170.8 Millions as of 31 Dec, 2025.

The top stock holdings of Birchview Capital, LP are KLAC, BMY, CMPX. The fund has invested 15.6% of it's portfolio in KLA CORPORATION and 9.6% of portfolio in BRISTOL-MYERS SQUIBB CO.

The fund managers got completely rid off AXOGEN INC (AXGN), KINIKSA PHARMACEUTICALS LTD (KNSA) and SCHOLAR ROCK HOLDING CORP (SRRK) stocks. They significantly reduced their stock positions in DOCGO INC (DCGO), INHIBRX BIOSCIENCES INC and ELUTIA INC (AZYO). Birchview Capital, LP opened new stock positions in LAM RESEARCH CORPORATION (LRCX), VERA THERAPEUTICS INC (VERA) and VERASTEM INC (VSTM). The fund showed a lot of confidence in some stocks as they added substantially to NEKTAR THERAPEUTICS (NKTR), INTELLIA THERAPEUTICS INC (NTLA) and BICYCLE THERAPEUTICS PLC (BCYC).

Birchview Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Birchview Capital, LP made a return of 10.83% in the last quarter. In trailing 12 months, it's portfolio return was 10.92%.

Performance
S&P 500

New Buys

Ticker	$ Bought
lam research corporation	6,903,520
vera therapeutics inc	2,228,160
verastem inc	1,158,000
10x genomics inc	962,290
illumina inc	786,960
biohaven ltd	670,231
pulmonx corp	553,766
rapt therapeutics inc	508,050

New stocks bought by Birchview Capital, LP

Additions

Ticker	% Inc.
nektar therapeutics	670
intellia therapeutics inc	425
bicycle therapeutics plc	200
ultragenyx pharmaceutical inc	181
solid biosciences inc	137
phathom pharmaceuticals inc	129
pharvaris n v	101
compass therapeutics inc	82.48

Additions to existing portfolio by Birchview Capital, LP

Reductions

Ticker	% Reduced
docgo inc	-93.47
inhibrx biosciences inc	-88.33
elutia inc	-63.02
uniqure nv	-60.89
alphatec holdings inc	-45.28
voyager therapeutics inc	-44.47
castle biosciences inc	-27.12
prothena corp plc	-19.67

Birchview Capital, LP reduced stake in above stock

Sold off

Ticker	$ Sold
applied therapeutics inc	-136,103
tela bio inc	-230,950
axogen inc	-2,124,350
inflarx nv	-67,000
avalo therapeutics inc	-394,010
kiniksa pharmaceuticals ltd	-1,164,900
karyopharm therapeutics inc	-183,022
scholar rock holding corp	-968,240

Birchview Capital, LP got rid off the above stocks

Sector Distribution

Birchview Capital, LP has about 70.4% of it's holdings in Healthcare sector.

Sector	%
Healthcare	70.4
Technology	19.6
Others	5.8
Energy	3.6

Market Cap. Distribution

Birchview Capital, LP has about 37.2% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
SMALL-CAP	35.1
LARGE-CAP	33.2
MID-CAP	18.8
UNALLOCATED	5.6
MEGA-CAP	4
MICRO-CAP	3.2

Stocks belong to which Index?

About 74% of the stocks held by Birchview Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	42.7
S&P 500	31.3
Others	26

Top 5 Winners (%)		%
VTYX	ventyx biosciences inc	185.0 %
	alumis inc	144.6 %
	structure therapeutics inc	126.0 %
OLMA	olema pharmaceuticals inc	100.4 %
	apogee therapeutics inc	90.0 %

Top 5 Winners ($)		$
	structure therapeutics inc	3.5 M
OLMA	olema pharmaceuticals inc	3.4 M
KLAC	kla corporation	3.0 M
BMY	bristol-myers squibb co	2.7 M
CMPX	compass therapeutics inc	2.3 M

Top 5 Losers (%)		%
OM	outset medical inc	-71.6 %
TMCI	treace medical concepts inc	-60.7 %
CORT	corcept therapeutics inc	-58.1 %
QURE	uniqure nv	-41.0 %
NTLA	intellia therapeutics inc	-35.4 %

Top 5 Losers ($)		$
CORT	corcept therapeutics inc	-3.2 M
QURE	uniqure nv	-1.9 M
NTLA	intellia therapeutics inc	-1.6 M
OM	outset medical inc	-0.9 M
TMCI	treace medical concepts inc	-0.9 M

Birchview Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Birchview Capital, LP

Birchview Capital, LP has 68 stocks in it's portfolio. About 54.6% of the portfolio is in top 10 stocks. CORT proved to be the most loss making stock for the portfolio. was the most profitable stock for Birchview Capital, LP last quarter.

Last Reported on: 13 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACAD	acadia pharmaceuticals inc	2.67	171,000	4,567,410	unchanged	0.00

ALKS	alkermes plc	0.82	50,000	1,399,000	unchanged	0.00

APLS	apellis pharmaceuticals inc	0.21	14,000	351,680	unchanged	0.00

APLT	applied therapeutics inc	0.00	0.00	0.00	sold off	-100

ATEC	alphatec holdings inc	0.22	18,058	379,940	reduced	-45.28

AVTX	avalo therapeutics inc	0.00	0.00	0.00	sold off	-100

AXGN	axogen inc	0.00	0.00	0.00	sold off	-100

AXSM	axsome therapeutics inc	0.65	6,061	1,106,980	added	1.02

AZYO	elutia inc	0.11	263,018	182,193	reduced	-63.02

BBIO	bridgebio pharma inc	0.39	8,688	664,545	unchanged	0.00

BCYC	bicycle therapeutics plc	1.92	462,700	3,275,920	added	200

BDSX	biodesix inc	1.14	286,804	1,950,270	unchanged	0.00

BMY	bristol-myers squibb co	9.56	302,842	16,335,300	reduced	-4.42

CADL	candel therapeutics inc	0.20	60,000	339,000	unchanged	0.00

CGEM	cullinan therapeutics inc	0.12	20,000	207,000	unchanged	0.00

CMPX	compass therapeutics inc	5.01	1,592,940	8,554,080	added	82.48

CORT	corcept therapeutics inc	1.37	67,200	2,338,560	unchanged	0.00

CSTL	castle biosciences inc	1.84	80,600	3,135,340	reduced	-27.12

CYTK	cytokinetics inc	1.12	30,000	1,906,200	unchanged	0.00

DCGO	docgo inc	0.03	49,908	43,809	reduced	-93.47